Assessing biomarkers of remission in female patients with anorexia nervosa (REMANO): a protocol for a prospective cohort study with a nested case-control study using clinical, neurocognitive, biological, genetic, epigenetic and neuroimaging markers in a French specialised inpatient unit.

Autor:	Duriez P; Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Team 'Vulnerability to Psychiatric and Addictive Disorders', Université Paris Cité, Paris, France p.duriez@ghu-paris.fr.; Clinique des Maladies Mentales et de l'Encéphale, Hôpital Sainte-Anne, GHU Paris Psychiatrie et Neurosciences, Paris, France., Tolle V; Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Team 'Vulnerability to Psychiatric and Addictive Disorders', Université Paris Cité, Paris, France., Ramoz N; Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Team 'Vulnerability to Psychiatric and Addictive Disorders', Université Paris Cité, Paris, France., Kimmel E; Clinique des Maladies Mentales et de l'Encéphale, Hôpital Sainte-Anne, GHU Paris Psychiatrie et Neurosciences, Paris, France., Charron S; Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, IMA-Brain, Université Paris Cité, Paris, France.; Service de Neuroradiologie, Hôpital Sainte-Anne, GHU Paris psychiatrie et neurosciences, Paris, France., Viltart O; Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Team 'Vulnerability to Psychiatric and Addictive Disorders', Université Paris Cité, Paris, France.; CNRS, UMR 9193 - SCALab - Sciences Cognitives et Sciences Affectives, University of Lille, Villeneuve d'Ascq, France., Lebrun N; Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Team 'Vulnerability to Psychiatric and Addictive Disorders', Université Paris Cité, Paris, France., Bienvenu T; Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Team 'Vulnerability to Psychiatric and Addictive Disorders', Université Paris Cité, Paris, France., Fadigas M; Clinique des Maladies Mentales et de l'Encéphale, Hôpital Sainte-Anne, GHU Paris Psychiatrie et Neurosciences, Paris, France., Oppenheim C; Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, IMA-Brain, Université Paris Cité, Paris, France.; Service de Neuroradiologie, Hôpital Sainte-Anne, GHU Paris psychiatrie et neurosciences, Paris, France., Gorwood P; Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Team 'Vulnerability to Psychiatric and Addictive Disorders', Université Paris Cité, Paris, France.; Clinique des Maladies Mentales et de l'Encéphale, Hôpital Sainte-Anne, GHU Paris Psychiatrie et Neurosciences, Paris, France.
Jazyk:	angličtina
Zdroj:	BMJ open [BMJ Open] 2024 Jun 25; Vol. 14 (6), pp. e077260. Date of Electronic Publication: 2024 Jun 25.
DOI:	10.1136/bmjopen-2023-077260
Abstrakt:	Background: Anorexia nervosa (AN) is a severe psychiatric disorder associated with frequent relapses and variability in treatment responses. Previous literature suggested that such variability is influenced by premorbid vulnerabilities such as abnormalities of the reward system. Several factors may indicate these vulnerabilities, such as neurocognitive markers (tendency to favour delayed reward, poor cognitive flexibility, abnormal decision process), genetic and epigenetic markers, biological and hormonal markers, and physiological markers.The present study will aim to identify markers that can predict body mass index (BMI) stability 6 months after discharge. The secondary aim of this study will be focused on characterising the biological, genetic, epigenetic and neurocognitive markers of remission in AN. Methods and Analysis: One hundred and twenty-five (n=125) female adult inpatients diagnosed with AN will be recruited and evaluated at three different times: at the beginning of hospitalisation, when discharged and 6 months later. Depending on the BMI at the third visit, patients will be split into two groups: stable remission (BMI≥18.5 kg/m²) or unstable remission (BMI<18.5 kg/m²). One hundred (n=100) volunteers will be included as healthy controls.Each visit will consist in self-reported inventories (measuring depression, anxiety, suicidal thoughts and feelings, eating disorders symptoms, exercise addiction and the presence of comorbidities), neurocognitive tasks (Delay Discounting Task, Trail-Making Test, Brixton Test and Slip-of-action Task), the collection of blood samples, the repeated collection of blood samples around a standard meal and MRI scans at rest and while resolving a delay discounting task.Analyses will mainly consist in comparing patients stabilised 6 months later and patients who relapsed during these 6 months. Ethics and Dissemination: Investigators will ask all participants to give written informed consent prior to participation, and all data will be recorded anonymously. The study will be conducted according to ethics recommendations from the Helsinki declaration (World Medical Association, 2013). It was registered on clinicaltrials.gov on 25 August 2020 as 'Remission Factors in Anorexia Nervosa (REMANO)', with the identifier NCT04560517 (for more details, see https://clinicaltrials.gov/ct2/show/record/NCT04560517). The present article is based on the latest protocol version from 29 November 2019. The sponsor, Institut National de la Santé Et de la Recherche Médicale (INSERM, https://www.inserm.fr/), is an academic institution responsible for the monitoring of the study, with an audit planned on a yearly basis.The results will be published after final analysis in the form of scientific articles in peer-reviewed journals and may be presented at national and international conferences. Trial Registration Number: clinicaltrials.govNCT04560517. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu